ABSTRACT The Western Washington Intracoronary Streptokinase In Myocardial Infarction Trial enrolled 250 patients with acute myocardial infarction. After the coronary angiographic diagnosis of thrombosis, patients were randomly assigned to receive either conventional therapy with heparin or intracoronary streptokinase followed by heparin. Of the 232 patients who survived at least 60 days, 207 (89%) underwent radionuclide ventriculographic determination of global and regional ejection fraction at a single institution at 62 + 35 days after infarction. In the first 100 patients, infarct size was also determined by quantitative single-photon emission tomographic imaging with thallium-201 (201T1) and expressed as a percentage of the left ventricle with a perfusion defect. Overall, global ejection fraction did not differ between patients treated with streptokinase (45.9 13.9%; n = 115) and control patients (46.1 + 14.4%; n = 92, p = NS). Similarly, the regional posterolateral, inferior, and anteroseptal ejection fraction did not differ between the two groups. Infarct size as measured by 201T1 tomography was 19.4 12.8% (n = 52) of the left ventricle for the streptokinase group and 19.6 11.8% (n = 48; p = NS) for the control group. When patients were compared within groups by electrocardiographic location of infarction, time to treatment, or the presence or absence of vessel opening, there were no significant differences between streptokinase and control patients. Statistical inclusion of the 18 patients who died early and were unavailable for study also failed to modify the results, except for a possible reduction in inferior infarct size as measured by 201T1 tomography. We conclude that global and regional left ventricular pump function and infarct size determined by 201T1 tomography did not differ substantially between patients receiving streptokinase and those receiving conventional treatment when measured 8 weeks after myocardial infarction. Circulation 70, No. 5, 867-875, 1984. WITH THE demonstration of coronary arterial thrombosis as a common denominator in patients with acute transmural myocardial infarction, therapeutic thrombolysis in this setting has become widespread. However, there are few controlled data comparing this form of therapy with conventional treatment. We determined the global and regional ejection fraction by ra 
WITH THE demonstration of coronary arterial thrombosis as a common denominator in patients with acute transmural myocardial infarction, therapeutic thrombolysis in this setting has become widespread. However, there are few controlled data comparing this form of therapy with conventional treatment. We determined the global and regional ejection fraction by radionuclide ventriculography as well as quantitative tomographic thallium-201 (201T1) perfusion of survivors of acute myocardial infarction in a randomized, multicenter trial comparing the use of intracoronary streptokinase with standard therapy. In this multicenter trial, the radionuclide studies were performed at a central laboratory 8 weeks after acute myocardial infarction.
Methods
Patient selection. Patients were treated in 13 hospitals in western Washington and one in Vancouver, B.C. Details of patient selection, baseline clinical characteristics, therapy, and 30 day mortality have been presented elsewhere.', 2 In brief, patients 75 years old or younger with typical clinical symptoms of acute myocardial infarction of 12 hr duration or less were eligible. Electrocardiographic entry criteria included ST segment elevation and/or a marked increase in T wave amplitude with or without new Q waves. Patients with other life-threatening illness and/or a contraindication to anticoagulation were excluded. Eligible patients, after giving informed consent, were taken to the cardiac catheterization laboratory and, after identification of thrombotic occlusion (total or subtotal) of a coronary artery not responsive to intracoronary nitroglycerin, were randomly assigned to receive either conventional therapy, including full-dose heparin, or intracoronary streptokinase. The randomization was stratified by duration of symptoms of less than or greater than 3 hr and by electrocardiographic location of infarction as anterior or inferior. Lateral infarction was grouped with anterior, and posterior infarction with inferior. Immediately after randomization, those patients assigned to receive intracoronary streptokinase were given the drug at a rate of 4000 U/ min as a continuous ostial or subselective catheter infusion or as bolus injections of 1000 U/ 15 sec in the coronary ostium. The infusion was maintained until reperfusion occurred and for 30 min thereafter, or until a total of 250,000 to 300,000 U had been given. All patients in both groups received full-dose heparin until oral anticoagulation with coumadin could be instituted. Other medications and therapy were prescribed at the discretion of personal physicians and included coronary bypass surgery or angioplasty in the early postinfarction period in some patients (see below).
A total of 250 patients underwent randomization, 134 to the streptokinase group and 116 to the control group. Anterior infarction was present in 1 16 (46%) and inferior infarction in 134 (54%). Fifty-five patients (22%) had symptoms of 0 to 3 hr duration and 195 (78%) had symptoms of 3 to 12 hr duration. The mean time from the onset of symptoms to randomization (and the concomitant administration of intracoronary streptokinase) was 276 min. There were no statistically significant differences between the control and treatment groups for the following baseline characteristics: age, sex, history of prior myocardial infarction, history of congestive heart failure, time to hospitalization, time to randomization, hypotension (systolic blood pressure <90 mm Hg), or ejection fraction determined by contrast angiography.2 Reperfusion or vessel opening was defined as any reduction in the percent stenosis or occlusion from the time of randomization to the termination of the angiogram. Repertusion occurred in 69% of the 132 patients in the streptokinase group (data were unavailable in two patients). In the 1 16 control patients, reperfusion occurred in 12% during the angiographic procedure cither spontaneously or in response to the radiographic contrast material, intracoronary nitroglycerin, or mechanical forces related to contrast injcctions.
Centralized radionuclide studies. After discharge from the hospital, each patient was asked to come to a central laboratory in Seattle for study of ventricular function and 01T 1 tomography. These studies were performed and the results were analyzed by investigators who were blinded to the treatment assignment. A total of 207 patients underwent late radionuclide ventriculographic studies at 62 ± 35 (1 SD) days after myocardial infarction. Twenty-eight of these patients had undergone coronary bypass surgery or percutaneous transluminal coronary angioplasty (17 in the streptokinase group, I1 in the control group) before undergoing radionuclide studies. This sample of patients represents 89% of survivors available for study at 8 weeks. The first 100 consecutive patients undergoing radionuclide studies also underwent rotational tomography for quantitation of the size of the myocardial perfusion defect. Ventricular-function. Radionuclide ventriculography was performed with patients at rest with electrocardiographically synchronized blood pool imaging. Red blood cells were labeled with 20 to 25 mCi 99"Tc and images were collected in the anterior and 45 degree left anterior oblique views (or a modification of the 45 degree view to best separate the right and left ventricles). Fourteen consecutive 40 msec images were collected, beginning with the clectrocardiographic R wave for a total of 300,000 counts/frame. A standard gamma camera and dedicated nuclear medicine computer were used with a low-energy, parallel-hole, high sensitivity collimator. Ejection fraction was calculated from the left anterior oblique image by subtracting end-systolic from end-diastolic counts (after background correction) and dividing this difference by the end-diastolic counts. For each frame of the cardiac cycle, a left ventricular region of interest was defined by a computer algorithm that initially used a thresholding and subsequently a two-dimensional first-derivative approach; the operator could override these automatically defined edges if they failed to correpond to the visually apparent cardiac borders. The accuracy and precision of these methods have been described elsewhere.-3 4 Next, by means of the left anterior oblique images as previously defined, the geometric center of activity was determined at end-diastole and anteroseptal, inferior, and posterolateral regional ejection fractions were calculated as illustrated in figure 1.
Inftirct size determinned by ' 1'Tl tomograzphy. Two millicuries of 201T1 was injected with patients at rest after an overnight fast.
Fifteen minutes later image collection was begun with a widefield of-view gamma camera (GE 400T, Milwaukee) that could rotate circumferentially about the patient's thorax.5-6 The camera was positioned with a fixed 22 cm radius of rotation to most closely approximate the chest wall at the cardiac apex. According to the observation of Larsson5 and as described in our labo- CIRCULATIONratory,6 image data were collected only over the 180 degrees closest to the myocardium. The long axis of the heart was assumed to lie at an approximate 30 degree angle from the frontal plane, and data were collected over 90 degrees to either side of that angle.6 Sixty four discrete view images, i.e., one image every 2.8 degrees, were then acquired over 180 degrees. The image format was 128 X 128 with a counting rate of approxinmately 2000 counts/sec. Each image was acquired for 20 sec for a total acquisition time of less than 22 min. A highresolution, low-energy collimator was used.
Projection images were low-pass filtered with a 5 x 5 spatial convolving kernel with a frequency cutoff at 0.285 cycles/projection pixel to reduce statistical noise. Each filtered projection was adjusted for the center of rotation and then back-projected into a 64 x 64 matrix. Six millimeter planes were reconstructed in the transverse plane and then further processed to obtain tomograms in the three orthogonal perspectives aligned with the cardiac axes as described previously. 7 8 In sum, a series of slices encompassing the entire heart was obtained for the cardiac short axis and the two orthogonal long-axis views (superior and right anterior oblique long axes).
Quantitation of the entire three-dimensional volume of the left ventricle proceeded as follows. From the summed short-axis slices, an operator estimated the geometric center by placement of a cross hair as shown in figure 2. This cross hair defined the axis for the two orthogonal long-axis views also shown in figure   2 . The edges of each long axis were defined by 45% of maximum activity in that slice. The apex and base were similarly defined. If a perfusion defect was present and no outer edge was found, the location of the edge for the prior slice was used or, alternatively, if no prior slice was available, symmetry about the long axis was assumed and the edge from the opposite wall was used. If no apical activity was present, the operator visually estimated the location of the apex. Right ventricular activity was excluded. These edges, as shown in figure 2, defined the two minor diameters of an elliptical region of interest for each slice. When summed, these slices represented the three-dimensional volume of myocardium over which quantitation was performed.
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Views RAO Long Axis Superior Long Axis Regional ejection fraction did not differ overall between the streptokinase-treated and control patients for any of the three regions. The posterolateral ejection fraction was 48.3 + 15.0% in the streptokinase group and 48.8 + 14.4% in the control group (p -NS); the inferior ejection fraction was 57.1 ± 13.9% for the streptokinase group and 57.2 ± 13.4% for controls (p = NS); the anteroseptal ejection fraction was 48.9 ± 12.9% for the streptokinase group and 48.1 + 12.5% for controls (p = NS). When the electrocardiographic location of infarction was considered, there were still no significant differences between streptokinase-treated and control patients for any of the three regional ejection fractions. When duration of symptoms of greater or less than 3 hr was considered, there were again no differences in any regional ejection fraction between streptokinase-treated and control patients. When either global or regional ejection fraction was analyzed by the nonparametric approach, incorporating patients who had died as the lowest rank, the conclusions above were unchanged. Similarly, both global and regional ejection fractions were unchanged whether or not patients with intervening coronary bypass surgery or angioplasty were included. . Infarct size determined by 201Tl tomography for all patients, those with anterior and inferior infarctions, and those treated with less than (LT) or greater than (GT) 3 hr of symptoms. There were no significant differences between streptokinase-treated and control patients in any group. Abbreviations as in figure 5 .
control patients (n = 48) (p = NS). Regional analysis of the infarct sizes showed no differences overall between the streptokinase and control groups for each of the five tomographic regions. When analyzed by electrocardiographic location of infarction, anterior infarct size did not differ between streptokinase-treated (27.8 ± 12.2%; n = 24) and control patients (23.1 ± 12.8%; n = 16, p = NS). Among patients with electrocardiographically inferior infarction, however, streptokinase-treated patients had significantly smaller infarct sizes: 12.2 ± 13.5% (n = 28) in streptokinase-treated vs 17.8 + 11.3% (n = 32) in control patients (p = .04). In this subgroup, most of the observed differences occurred because slightly more control than treated patients with inferior infarction had had prior myocardial infarctions. The observed difference in infarct size for inferior infarctions was not significantly different (p > .05) after adjustment for history of infarction.
There were no differences in tomographic infarct size between control and streptokinase-treated patients in the subsets with symptoms of less than or greater than 3 hr duration. Infarct size in patients with symptoms of less than 3 hr duration was 19.0 ± 11.4% (n = 10) in streptokinase-treated vs 18.5 + 10.2% (n = 9) in control patients (p = NS). For those with symptoms of more than 3 hr duration, infarct size was 19.5 ± 13.6% in streptokinase-treated (n = 42) and 19.0 ± 12.5% in control patients (n = 39, p = NS). Similarly, the size of the tomographic perfusion defect was not related to opening of the occluded vessel. Infarct size was 22.2 + 12.7% (n = 50) in those with closed vessels vs 18.0 ± 12.5% (n = 43, p = NS) in those with opened vessels. However, a minority of patients were treated within 3 hr and only two patients were treated in under 2 hr.
In patients who died early, the follow-up infarct size could not be known. Since there were more deaths in the control group, the data were reanalyzed by the relative rank of the infarct size for each patient. Infarct sizes for patients who died were included as the highest rank, corresponding to large infarcts. In these analyses, the overall infarct size still did not differ between the streptokinase and control groups. When analyzed by anatomic region on the tomograms, there was a significant reduction in infarct size within the inferior zone only (p = .04). Infarct size in the remaining four regions did not differ between the streptokinase and control groups. When analyzed by the electrocardiographic location of infarction, there were no differences for global or regional infarct size for anterior myocardial infarction. However, for inferior infarctions the global or overall infarct size was significantly smaller for the streptokinase group (p = .03), i.e., this result was identical to that of the analysis excluding the deaths. Infarct size and ejection fraction were closely related; the correlation coefficient between the two was -.74.
Stepwise multiple regression. Stepwise multiple regression analysis was used to protect against confounding of the treatment effect with baseline patient characteristics. The analyses were used to determine the patient characteristics most closely related to the measures of myocardial damage studied and to analyze the difference in outcome for treated and untreated patients after adjustment for these characteristics. The analysis of infarct size selected anterior infarct (p < .0001) and previous myocardial infarction (p = .003) as most predictive of tomographic infarct size. Adjustment for these variables did not result in a difference in infarct size for streptokinase-treated patients compared with untreated patients. The analysis of ejection fraction selected anterior infarct (p -.01) and baseline contrast angiographic ejection fraction (p < .0001) as most closely related to follow-up ejection fraction. There was no difference in follow-up ejection fraction for treated and untreated patients after adjustment of the comparison for these variables.
Summary. There was no overall reduction in infarct size between streptokinase-treated and control patients whether or not deaths were considered. When deaths were included there was a possible reduction in infarct size favoring the streptokinase group only in the inferior region. Whether or not this has biologic significance is not clear, given the large number of statistical tests used. These results were the same whether or not the subset of patients undergoing intervening coronary bypass surgery or angioplasty were included.
Discussion
In this study, patients from several institutions came to a central laboratory for standardized evaluation of both global and regional left ventricular function by radionuclide ventriculography. One hundred of these patients also underwent a three-dimensional measure of infarct size. Overall, there were no differences between the streptokinase-treated and control patients in either infarct size or ventricular function, suggesting no substantial benefit or harm from the experimental therapy.
The comparability of these results for global function and infarct size showing no demonstrable benefit to survivors supports the biologic certainty of this conclusion. That is, these two tests are relatively independent, assessing myocardial damage from two differing perspectives, one measuring ventricular pump function and the other myocardial perfusion. Technically, the two studies also differed. The 207T1 tomogram, for example, was reconstructed three-dimensionally by computer techniques, whereas the radionuclide ventriculogram was performed with the standard planar approach. Thus neither infarct size, a direct measure of myocardial damage, nor residual pump function on either a global or regional basis were different overall between streptokinase-treated and control patients as evaluated 8 weeks after myocardial infarction.
An unexpected feature of the data is the lack of any relationship between the time to treatment and the infarct size or ventricular function. All experimental animal data and much of the available clinical literature show that the degree of myocardial salvage relates directly to the elapsed time to thrombolysis. 11-11 A possible explanation for the results of this study is that the times to treatment were simply too long. The mean time to vessel opening was about 5 hr; only 22% of patients had symptoms of less than 3 hr duration. The earliest treated were two patients who had had symptoms for 2 hr. A similar finding was the lack of any relationship between the radionuclide measures and the presence or absence of vessel opening. Since vessel opening is the presumed sine qua non for possible myocardial salvage, the lack of any relationship might again support the hypothesis that as applied in this study, therapy was simply too late and even if vessel opening occurred it was generally too late to be of benefit in surviving patients. Since no patients were treated within 1 hr of the onset of symptoms and only two within 2 hr, our data cannot be extrapolated to suggest that very early treatment would not be more beneficial.
The radionuclide studies used in this study were performed relatively late, an average of 8 weeks after infarction. This was necessitated primarily by the study design, in which hospitals from throughout the western half of the state of Washington participated. However, late studies probably do reflect net myocardial damage after infarction. Peri-infarctional ischemic changes should have largely resolved by this time.'4 Similarly, the increase in sympathetic activity associated with myocardial infarction would have normalized. Analysis of contrast left ventriculograms at the time of intracoronary administration of streptokinase has commonly shown hyperkinesis in noninvolved areas, so that the global ejection function was relatively unaffected. When studied remote from infarction, hyperkinesis is much less commonly observed. 16 Thus, in our late studies, global and regional ejection fraction should be sensitive indicators of the extent of residual myocardial damage. The validity of late studies presupposes that intervening acute infarction has not occurred; this was the case in our sample, with no patient having an interim rehospitalization for acute infarction. A small proportion of patients (12%) did, however, undergo coronary bypass surgery or angioplasty resting ventricular function and perfusion could have been altered by this therapy. The overall results, however, were the same whether or not these patients were included.
Quantitative 
